Joseph Klein III, a member of Ionis Pharmaceuticals' board, sold 22,321 shares of the company's common stock on April 1, 2026, in a series of transactions that collectively amounted to roughly $1.69 million. Reported execution prices on those trades ranged from $75.503 to $75.954 per share. The move comes as Ionis shares have recorded a 160.5% gain over the last 12 months and were trading at $74.79 at the time of the report.
Alongside the share disposals, Klein exercised stock options that produced an additional 22,321 shares. The option conversions comprised 12,000 shares at an exercise price of $38.06 per share and 10,321 shares at $41.08 per share. The combined value attributed to those exercised options was reported at $880,706.
After completing the sales and option exercises, Klein's reported direct ownership in Ionis stands at 11,014 shares. He also maintains indirect ownership of 100 shares that are held by his son.
Context on valuation and analysis services - For readers seeking deeper quantitative valuation and performance metrics for Ionis Pharmaceuticals, specialized services referenced in the report provide Fair Value estimates and additional analytic tools for the company, which is cited with a market capitalization of $12.35 billion.
Commercial and analyst developments - Ionis announced a new wholesale acquisition cost for Tryngolza, setting pricing at $40,000 for the severe hypertriglyceridemia indication. That price is notably above the previously guided range of $10,000 to $20,000.
Following the pricing disclosure, several broker-dealers updated or reiterated their coverage assessments:
- Barclays increased its price target for Ionis shares to $106 and maintained an Overweight rating.
- RBC Capital reiterated an Outperform rating with a $95 price target, noting the implications of the pricing for both severe hypertriglyceridemia and familial chylomicronemia syndrome indications.
- BofA Securities kept a Buy rating and a $100 price target after the pricing announcement.
- H.C. Wainwright reiterated a Buy rating with a $120 price target following regulatory progress in Europe for Ionis’ partner's drug candidate.
- William Blair reaffirmed an Outperform rating, citing the Tryngolza pricing update.
These items together outline a period of active corporate and market developments for Ionis Pharmaceuticals, encompassing insider stock activity, option exercises, updated commercial pricing for a key product, and a series of analyst responses.